AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMT-151’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMT-151 is under development for the treatment of solid tumor including endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic ductal adenocarcinoma, malignant pleural mesothelioma, triple-negative breast cancer (TNBC), lung adenocarcinoma, non-small cell lung cancer (NSCLC) and unspecified indication. It is administered through intravenous route.
Multitude therapeutics overview
Multitude therapeutics is a Pharmaceuticals and Healthcare company that Develop antibody-drug conjugates. The company is headquartered in Redwood city, California, The U.S.
For a complete picture of AMT-151’s drug-specific PTSR and LoA scores, buy the report here.